Gain Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GANX Nasdaq 2836 www.gaintherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gain Therapeutics, Inc.

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease - Mar 14th, 2025 11:45 am
Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - Mar 6th, 2025 12:55 pm
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - Feb 6th, 2025 1:45 pm
Gain Therapeutics To Participate in Upcoming Investor Conferences - Feb 5th, 2025 1:30 pm
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy - Jan 16th, 2025 5:00 pm
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 - Jan 8th, 2025 1:00 pm
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director - Jan 7th, 2025 12:00 pm
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM - Dec 25th, 2024 12:40 pm
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease - Dec 23rd, 2024 12:30 pm
Gain Therapeutics To Present At Biotech Showcase 2025 - Dec 11th, 2024 1:30 pm
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update - Nov 14th, 2024 9:05 pm
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - Oct 23rd, 2024 12:00 pm
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Oct 15th, 2024 11:00 am
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference - Oct 9th, 2024 12:30 pm
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - Oct 7th, 2024 11:00 am
Gain Therapeutics to Participate at Upcoming Investor Conferences - Oct 3rd, 2024 11:00 am
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - Sep 30th, 2024 11:00 am
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease - Sep 26th, 2024 11:00 am
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024 - Sep 19th, 2024 11:00 am